Immunocore Holdings plc filed a Form 8-K with the SEC on November 6, 2026, furnishing a press release announcing its financial results for the third quarter ended September 30, 2026, along with other recent corporate updates.

Key Highlights

  • Reporting period: Third quarter ended September 30, 2026.
  • Filing date: November 6, 2026, the same date as the earliest event reported.
  • Exchange listing: American Depositary Shares trade on NASDAQ:IMCR, each representing one ordinary share with a nominal value of £0.002 per share.
  • Exhibit furnished: Press Release dated November 6, 2026, attached as Exhibit 99.1 and incorporated by reference.
  • Signed by: Bahija Jallal, Ph.D., Chief Executive Officer, on behalf of Immunocore Holdings plc.
  • Furnished, not filed: The information in Item 2.02 and Exhibit 99.1 is furnished and, according to the filing, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Immunocore Furnishes Q3 2026 Results Press Release Under Item 2.02

According to the filing, Immunocore Holdings plc, incorporated in England and Wales and headquartered at 92 Park Drive, Milton Park Abingdon, Oxfordshire, United Kingdom, submitted the Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The company disclosed that on November 6, 2026, it issued a press release covering its financial results for the third quarter ended September 30, 2026, as well as other recent corporate updates.

The filing makes clear that the press release, attached as Exhibit 99.1, is being furnished rather than filed with the SEC. The company stated that the information "shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act," except where expressly specified. The 8-K was signed by Chief Executive Officer Bahija Jallal, Ph.D., on behalf of Immunocore Holdings plc.

Immunocore's American Depositary Shares, each representing one ordinary share with a nominal value of £0.002 per share, are listed on The Nasdaq Stock Market LLC under the trading symbol IMCR. The company is not classified as an emerging growth company, as indicated by the check boxes on the cover page of the filing.

What Was Disclosed

Immunocore Holdings plc filed an 8-K on November 6, 2026, furnishing a press release as Exhibit 99.1 that announced the company's financial results for the third quarter ended September 30, 2026, and other corporate updates.